The test detects and differentiates respiratory infections caused by Influenza (Flu) A and B as well as SARS-CoV-2. Credit: NIAID / Flickr (Creative Commons).

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Visby Medical’s new Respiratory Health point-of-care test, a rapid polymerase chain reaction (PCR) device, for use in Clinical Laboratory Improvement Amendments (CLIA)-waived settings.

The Visby Medical Respiratory Health Test has been designed for the detection and differentiation of upper respiratory infections caused by Influenza (Flu) A and B as well as SARS-CoV-2.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is an ‘instrument-free’ platform that fits in the palm of the user’s hand and provides results in less than 30 minutes in point-of-care settings.

Additionally, the test allows clinicians to accurately diagnose and provide treatment for patients. 

Visby stated that the Centers for Disease Control and Prevention (CDC) and the Infectious Disease Society of America recommend clinicians use rapid molecular assays rather than rapid influenza antigen diagnostic tests (RIDTs) to improve detection for outpatients.

See Also:

Visby Medical chief medical officer Dr Gary Schoolnik said: “Accurate, rapid, point-of-care testing can help physicians prescribe appropriate antiviral medications, minimise viral transmission in waiting rooms and improve patient satisfaction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Use of the Visby Respiratory Health Test at the point of care in urgent care clinics and emergency rooms will transform how patients with respiratory symptoms are diagnosed and treated.”

The project to develop the new PCR test has been supported in whole or in part with federal funds.

These funds came from the US Administration for Strategic Preparedness and Response, Department of Health and Human Services, and Biomedical Advanced Research and Development Authority (BARDA).

Last March, the company received $25.5m in additional funding from BARDA for the development of the Rapid Flu-COVID PCR Test.